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Abstract
Background: Intra-amniotic Candida albicans (C. Albicans) infection is associated with preterm birth and high
morbidity and mortality rates. Survivors are prone to adverse neurodevelopmental outcomes. The mechanisms
leading to these adverse neonatal brain outcomes remain largely unknown. To better understand the mechanisms
underlying C. albicans-induced fetal brain injury, we studied immunological responses and structural changes of the
fetal brain in a well-established translational ovine model of intra-amniotic C. albicans infection. In addition, we
tested whether these potential adverse outcomes of the fetal brain were improved in utero by antifungal treatment
with fluconazole.
Methods: Pregnant ewes received an intra-amniotic injection of 107 colony-forming units C. albicans or saline
(controls) at 3 or 5 days before preterm delivery at 0.8 of gestation (term ~ 150 days). Fetal intra-amniotic/intra-
peritoneal injections of fluconazole or saline (controls) were administered 2 days after C. albicans exposure. Post
mortem analyses for fungal burden, peripheral immune activation, neuroinflammation, and white matter/neuronal
injury were performed to determine the effects of intra-amniotic C. albicans and fluconazole treatment.
Results: Intra-amniotic exposure to C. albicans caused a severe systemic inflammatory response, illustrated by a
robust increase of plasma interleukin-6 concentrations. Cerebrospinal fluid cultures were positive for C. albicans in
the majority of the 3-day C. albicans-exposed animals whereas no positive cultures were present in the 5-day C.
albicans-exposed and fluconazole-treated animals. Although C. albicans was not detected in the brain parenchyma,
a neuroinflammatory response in the hippocampus and white matter was seen which was characterized by
increased microglial and astrocyte activation. These neuroinflammatory changes were accompanied by structural
white matter injury. Intra-amniotic fluconazole reduced fetal mortality but did not attenuate neuroinflammation and
white matter injury.
Conclusions: Intra-amniotic C. albicans exposure provoked acute systemic and neuroinflammatory responses with
concomitant white matter injury. Fluconazole treatment prevented systemic inflammation without attenuating
cerebral inflammation and injury.
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Background
Preterm birth is associated with chorioamnionitis which
is defined as inflammation of the fetal membranes and
amniotic fluid caused by microbial invasion [1, 2]. The
microorganisms most frequently associated with this
condition include Ureaplasma species, Mycoplasma
hominis, and Gardnerella vaginalis, all of which most
commonly originate from the lower reproductive tract
[3]. These microorganisms and/or inflammatory media-
tors in the amniotic cavity can cause a fetal inflamma-
tory response syndrome (FIRS) [4–6]. Chorioamnionitis
and subsequent FIRS are independent risk factors for ad-
verse outcomes, including injury of the fetal brain [5, 7].
Adverse neurodevelopmental outcomes result from diffuse
cerebral inflammation and white matter injury, periven-
tricular leukomalacia, and intraventricular hemorrhage
[5, 8, 9]. These conditions are associated with a high
mortality rate, and survivors are predisposed to long-
term morbidity including mental retardation, impaired
learning, visual disorders, and in severe cases, cerebral
palsy [7, 8, 10].
The pathophysiology of chorioamnionitis can also include
viral and fungal species [4, 11, 12]. Candida albicans
(C. albicans) is a commensal fungus of the gastro-intestinal
tract which can be asymptomatic in the vaginal microbiota
with increasing incidence during pregnancy [13, 14]. Intra-
amniotic C. albicans infections are associated with high
mortality rates and severely impaired neurodevelopmental
outcomes [13–16] in which the mechanisms linking fetal
exposure to neurological pathologies remain essentially
unstudied. We hypothesized that antenatal exposure to
C. albicans caused a neuroinflammatory response and sub-
sequent white matter injury, which we tested by exposing
fetal sheep to intra-amniotic C. albicans [16, 17].
In two clinical cases, intra-amniotic C. albicans infec-
tions resolved after oral and intra-amniotic fluconazole
(F) [13]. Fluconazole is the most frequently used antifun-
gal in C. albicans infections, and inhibits ergosterol syn-
thesis, which is an essential component of fungal cell
membranes [18]. We therefore further hypothesized that
fetal intra-amniotic and intra-peritoneal administration
of fluconazole would reduce the neuroinflammatory re-
sponse and subsequent white matter injury to the fetal
brain. Accordingly, systemic immune activation, neuro-
inflammation, and structural white matter injury were
assessed in the fetal sheep exposed to intra-amniotic C.
albicans and treated with fluconazole.
Methods
Experimental design
The study was approved by and performed according to
the guidelines of the animal ethics committee of the Uni-
versity of Western Australia (Perth, Australia). Twenty-six
date-mated Merino ewes with singleton pregnancies
were randomly assigned to receive an intra-amniotic
injection of saline (2 mL) as a control or C. albicans
(107 colony-forming units [CFU], Western Australian
clinical isolate) [16]. After 2 days, an intra-amniotic/-peri-
toneal injection of fluconazole (30 mg per injection, Claris
Life Sciences Limited, Chacharwadi-vasana, Ahmedabad-
382 213, India) or saline (controls) was administered with
delivery after 1 and 3 days (Fig. 1). Intra-amniotic injec-
tions were performed as previously described [17].
We did not include a 5-day C. albicans-only group
since previous results with this model indicated that
5 days exposure to C. albicans alone was lethal [16, 17].
Given the survival of the 5-day C. albicans-/fluconazole-
treated group, we have concluded that fluconazole in
this model increases survival [16, 17].
Tissue collection
Fetuses were delivered by Cesarean section at 0.8 of ges-
tation (term ~150 days) [19], equivalent of 32–34 weeks
human gestation [20], and euthanized with intravenous
pentobarbitone (100 mg/kg). Amniotic fluid, blood, and
cerebrospinal fluid (CSF) were collected at delivery, and
cultures for C. albicans were performed [16]. Briefly, am-
niotic fluid (100 μL) was inoculated onto Difco Sabouraud
Dextrose agar and incubated at 37 °C for 48 h. Blood
(2 mL) and liquor (1 mL) were inoculated into BACTEC
Fig. 1 Experimental setup. Animals were exposed to C. albicans for 3 or 5 days in the absence or presence of intra-amniotic (IA)/intraperitoneal
(IP) fluconazole (F). Control animals received intra-amniotic (IA) injection with saline. Fetuses were delivered at 0.8 of gestation
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Peds Plus/F culture vials (Becton Dickinson, Franklin
Lakes, NJ) and incubated aerobically at 37 °C for 72 h [16].
Brains were immersion-fixated in 4 % paraformaldehyde.
Enzyme-linked immunosorbent assay interleukin-6
Plasma interleukin-6 (IL-6) concentrations were assessed
as an indication for systemic inflammation using a sheep-
specific sandwich enzyme-linked immunosorbent assay
(ELISA). First, 96-well plates were pre-coated with 100 μL
of mouse anti-ovine monoclonal antibody (MAB1004,
Millipore, Darmstadt, Germany, working concentration
1:200) overnight at 4 °C. Plates were washed three times
with 0.05 % Tween-20 in phosphate-buffered saline
(PBST). Non-specific binding was blocked with a blocking
buffer (1 % bovine serum albumin [BSA] in PBST) for 1 h
followed by a washing step.
Protein standards were prepared by serial dilution of
recombinant IL-6 (ImmunoChemistry Technologies,
Bloomington, MN, USA). Plasma samples (100 μL) were
loaded per well in duplicate and incubated for 2 h at
room temperature. Unbound protein was omitted by
washing with PBST, followed by incubation with detec-
tion antibody (rabbit anti-ovine IL-6, AB1839, Millipore,
Darmstadt, Germany, working concentration 1:500) for
60 min and subsequent washing. Next, each well was in-
cubated for 30 min with 100 μL of a goat anti-rabbit
HRP (Jackson ImmunoResearch Laboratories Inc, West
Grove, PA, USA, working concentration 1:500) followed
by washing and incubation with 3,3′,5,5′-tetramethyl-
benzidine (TMB) substrate solution for 15 min at room
temperature. The reaction was stopped by addition of
50 μL 2N sulfuric acid to each well. Plates were then
read on an ELISA plate reader at 450 nm.
Histology and immunohistochemistry
The right hemisphere was divided into four defined ana-
tomical regions. Serial coronal sections of identical
thickness (4 μm) of the region containing the posterior
hippocampus and mid-thalamus were cut with a Leica
RM2235 microtome. Within this region, we analyzed the
hippocampus and the cerebral white matter since these
regions are most affected following intra-uterine in-
fection at this developmental stage [21]. All stainings
were performed in series (every 15th section), and four
sections per staining per animal were analyzed.
Hematoxylin and eosin (H&E) and periodic acid-Schiff
(PAS) stainings were performed for morphological and
anatomical analysis and for identification of pseudohy-
phae of C. albicans, respectively. Adjacent sections were
stained for ionized calcium-binding adaptor molecule 1
(IBA-1) (Wako Pure Chemical Industries, Osaka, Japan)
for microglia, glial fibrillary acidic protein (GFAP)
(DAKO Z0334) for astrocytes, myelin basic protein
(MBP) (Merck Millipore, MAB386) for myelin sheaths,
2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase)
(Sigma, C5922) for mature myelin-producing oligoden-
drocytes, oligodendrocyte transcription factor 2 (Olig2)
(Millipore, AB9610) for oligodendrocyte lineage cells,
cluster of differentiation (CD) 68 (DAKO, M0718) for
active microglia/phagocytizing macrophages, myeloper-
oxidase (MPO) (DAKO, A0398) for neutrophils, CD3
(DAKO A0452) for T-lymphocytes, Ki67 (DAKO,
M7240) for cell proliferation, and cleaved caspase-3 (cell
signaling, #9661) for apoptosis.
Sections were deparaffinized and rehydrated. Endogen-
ous peroxidase activity was inactivated with 0.3 % H2O2
treatment. For every immunolabeled stain with the ex-
ception of GFAP and CD68, antigen retrieval was per-
formed by microwave boiling of tissue sections in citrate
buffer, pH 6.0. For CD68, antigen retrieval was per-
formed with proteinase K (DAKO, S3004) treatment for
5 min at 37 °C. Nonspecific binding was blocked by in-
cubation with 5 % BSA (MBP, Olig2, and CD3) or goat
serum in phosphate-buffered saline (PBS) (IBA-1, GFAP,
CNPase, CD68, MPO, and Ki67). Sections were incu-
bated overnight at 4 °C in a closed humidity chamber
with primary antibody (IBA-1, GFAP, MBP, CNPase, and
caspase-3 1:1000; Olig2, MPO, and CD3 1:200; Ki67
1:100; CD68 1:50) and subsequently incubated with
the specific secondary antibody. Immunostaining was
enhanced with a Vectastain ABC peroxidase Elite kit
(Vector Laboratories Inc, Burlingame, CA) followed by a
(nickel) 3,3'-diaminobenzidine (DAB) staining and 0.1 %
Nuclear Fast Red (Olig2, CD3, Ki67, and caspase-3) or
Mayer’s hematoxylin (CD68 and MPO) for background
staining. Sections were dehydrated and cover-slipped.
To identify the mature and total number of oligoden-
drocytes, an immunohistochemical procedure for sequen-
tial double staining of CNPase and Olig2 was applied. In
this procedure, sections were treated as described above
and incubated with the anti-CNPase antibody, followed by
incubation with a biotinylated anti-mouse secondary anti-
body and visualization with 3,3'-diaminobenzidine (DAB;
Dako). Before incubation with the Olig2 primary antibody,
slides were blocked again with 5 % BSA for 60 min. Cells
that stained positive for Olig2 were visualized by Histo-
Green (Linaris, E109).
Immunofluorescence
To identify C. albicans in the brain tissue, immunofluor-
escence staining was performed as described previously
[17] using a rabbit anti-C. albicans antibody (Meridian
Life Science, Memphis, TN, working concentration 1:50)
and appropriate Alexa Fluor 594-labeled secondary anti-
body (working concentration 1:200). Briefly, sections
were deparaffinized, rehydrated, and incubated in 0.25 %
ammonia dissolved in 70 % ethanol for 1 h on a shaker.
Antigen retrieval was performed using citrate buffer
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(pH 6.0) in a microwave oven. Nonspecific binding was
blocked by incubation with 10 % goat serum for 1 h
followed by overnight incubation with primary anti-
C.albicans antibody dissolved in 0.1 % PBS with 0.2 %
Tween-20. For fluorescence staining, Alexa Fluor-
conjugated secondary antibody was used followed by
incubation in 0.3 % Sudan Black Solution to reduce
auto-fluorescence. Counterstaining was done with the
fluorescent nuclear marker Hoechst.
To assess neuronal injury, a Fluoro-Jade C staining
was performed, which is a specific marker for identifica-
tion of degenerating neurons [22, 23]. In this procedure,
sections were deparaffinized, rehydrated, and immersed
in 0.06 % potassium permanganate with 0.01 % Hoechst
for 10 min. Before immersing in the Fluoro-Jade C solu-
tion, sections were rinsed in running tap water for 1–2
min. Immersion in the Fluoro-Jade C solution (Milli-
pore, AG325) (0.01 % stock solution in 0.1 % acetic acid)
was performed in the dark for 10 min. Sections were
washed with distilled water and subsequently air-dried at
50 °C. Finally, sections were cleared with xylene for
1 min before being cover-slipped using DPX.
Qualitative analysis
H&E-stained sections were analyzed by three independ-
ent investigators and two neuropathologists, blinded to
the experimental groups, to assess overall brain structure
and inflammatory changes. The absence of tissue autoly-
sis in our sections was confirmed by neuropathologists.
The sections were examined for the presence of hemor-
rhages, gliosis, (cytotoxic) edema, abscess formation, and
structural damage, including cyst formation. C. albicans
fluorescent and PAS-stained sections were examined for
the presence of C. albicans.
Quantitative analysis
For the analysis of IBA-1, GFAP, MBP, CNPase, Olig2,
and CD68 immunoreactivity, digital images of the hippo-
campus, white matter (WM), and periventricular white
matter (PVWM) were acquired using an Olympus AX-
70 microscope (Olympus, Tokyo, Japan) equipped with a
black and white digital camera. From each section, one
picture of the hippocampus was taken at a ×20 magnifi-
cation, and images in the WM were taken at a ×100
magnification of the gliotic foci and 4–6 consecutive
images of the PVWM. The area fraction of IBA-1, GFAP,
and MBP immuno-reactivity was determined with a stand-
ard intensity threshold to determine positive staining using
QWin Pro V 3.5.1 software (Leica, Rijswijk, The
Netherlands). Blood vessels and artifacts were excluded
from analysis. The CNPase- and Olig2-positive cells were
counted using QWin software and expressed as cells/mm2.
Ki67-, caspase-3-, CD3-, and MPO-positive cells were
counted in all brain regions, focusing on the cerebral vascu-
lature. The digital images were acquired and analyzed by an
independent observer who was blinded to the experimental
groups. Fluoro-Jade C/Hoechst stainings were examined
using the Olympus AX-70 fluorescent microscope.
Data analysis
Statistical analysis was performed with GraphPad Prism
software (version v5.0; GraphPad Software Inc., La Jolla,
CA, USA). Results were analyzed using the non-
parametric Kruskal-Wallis test with Dunnett’s post-hoc
testing to compare different groups. Results are given as
mean and standard error of the mean (SEM) with signifi-
cance at p < 0.05.
Results
C. albicans culture
C. albicans colonial morphology was confirmed by
growth on Brilliance Candida Agar (Oxoid, Adelaide,
Australia). Positive cerebrospinal fluid (CSF) cultures for
C. albicans were detected in 67 % (4/6) of the 3-day C.
albicans-exposed animals and in 50 % (3/6) of the 3-day
C. albicans-/fluconazole-treated animals (Table 1). No
positive cultures were present in the 5-day C. albicans-/
fluconazole-treated group (0/5). Control animals had
negative CSF cultures. Results of amniotic fluid and blood
cultures were previously published by Maneenil and
colleagues and are also summarized in the table [16].
No evidence of C. albicans invasion in the brain
Despite substantial numbers of animals with positive
CSF cultures for C. albicans, PAS and immunofluores-
cent staining did not identify C. albicans in the paren-
chyma of the brains of any of the experimental
groups (data not shown).
Table 1 Candida albicans cultures
Control 3-day C. albicans 3-day C. albicans
and fluconazole
5-day C. albicans
and fluconazole
Cerebrospinal fluid 0/6 4/6 3/6 0/5
Fetal blooda 0/6 4/6 5/6 3/5
Amniotic fluida 0/6 6/6 6/6 5/5
The ratio of C. albicans-positive/total cultures are depicted
aBased on previously published data [16]
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Pro-inflammatory cytokine response
Significantly elevated plasma IL-6 concentrations were
found in 50 % (3/6) of the 3-day C. albicans-exposed an-
imals when compared to controls (Fig. 2). Forty percent
(2/5) of the 5-day C. albicans-/fluconazole-treated ani-
mals demonstrated elevated plasma concentrations of
IL-6; however, statistical significance was not reached.
Plasma IL-6 concentrations in the controls, 1-day flu-
conazole- and 3-day C. albicans-/fluconazole-treated an-
imals, were not detectable.
Qualitative analysis of the brain
Qualitative analysis of H&E-stained sections revealed no
evidence of structural changes including intraventricular
hemorrhages and cystic lesions in any of the experimental
groups. However, the brains of C. albicans-exposed animals
had increased cell density in the white matter which pri-
marily consisted of glial cells and blood-derived macro-
phages, that cannot be distinguished from microglia
(Fig. 3). These gliotic lesions were primarily present in the
gyral crests of the white matter and were more pronounced
in 100 % (5/5) of animals of the 5-day C. albicans-/flucona-
zole-treated group (Fig. 3c, d) and in 67 % (8/12) of animals
in the 3-day C. albicans-exposed groups. Control animals
had mild to no gliotic lesions (Fig. 3a, b). Interestingly, the
subcortical white matter was not affected (Fig. 3c).
Antenatal exposure to C. albicans caused microglia/
macrophage and astrocyte activation in the hippocampus
and white matter
The neuroinflammatory changes, as indicated by the more
pronounced presence of gliotic foci, in C. albicans-
exposed animals were further evaluated by immunohisto-
chemical analysis of the microglial marker IBA-1. This
staining demonstrated IBA-1 immunoreactivity (IR)
distributed throughout the white matter in distinct foci in
the C. albicans-exposed animals. These foci were primar-
ily detected at the gyral crests of the white matter
which corresponds with the increased cell density
found in the H&E staining. This finding is substantiated
by an increase of IBA-1 IR within these foci after intra-
amniotic exposure to C. albicans irrespective of flucon-
azole treatment compared to the control group and/or
1-day fluconazole group (Fig. 4a–d). These foci com-
prised microglia of both ramified and amoeboid
morphology. However, quantification of microglial acti-
vation based on microglial morphology was hampered
by the high cell density within these foci. Immunoreac-
tivity of CD68, representative for activated microglia/
phagocytizing macrophages [24], was increased in the
5-day C. albicans/fluconazole group compared to con-
trols (Fig. 4e–h). No significant changes in IBA-1 im-
munoreactivity in the periventricular white matter
were observed. However, in 17 % (1/6) of the 3-day
C. albicans animals and 60 % (3/5) of the 5-day C.
albicans/fluconazole animals, foci containing CD68-
positive cells were found in the periventricular white
matter (data not shown). Besides an increase in IBA-
1 immunoreactivity, an increase of the astrocyte
marker glial fibrillary acidic protein (GFAP) was
found in the hippocampus after intra-amniotic ex-
posure to C. albicans compared to the control group
and/or 1-day fluconazole group (Fig. 5). Administra-
tion of fluconazole irrespective of pre-exposure to
C. albicans did not induce changes in IBA-1 or GFAP
immunoreactivity.
Antenatal exposure to C. albicans caused focal white
matter disturbances with loss of mature oligodendrocytes
There was reduced MBP immunoreactivity within
regions of overt microglial activation in the 3-day C.
albicans-exposed animals. In addition, myelin texture
was disturbed in all C. albicans-exposed animals
whereas no myelin disturbances were observed in
control animals (Fig. 4i–l). The apparent loss of MBP
IR and altered texture of myelin prompted us to fur-
ther investigate the ratio between mature and total
oligodendroglial lineage cells. Double staining for
CNPase and Olig2 revealed a significant decrease of
CNPase-positive cells in the 3-day C. albicans/flucon-
azole and 5-day C. albicans/fluconazole groups
whereas the number of Olig2-positive cells remained
identical, thereby resulting in a decreased ratio of
mature vs. total oligodendrocytes in these animals
(Fig. 6a–e).
Fig. 2 Plasma IL-6 concentrations following intra-amniotic C. albicans
and/or fluconazole treatment. For statistical analysis, undetectable
values were assigned an arbitrary value of 1 pg/mL. *p≤ 0.05 vs.
control; #p≤ 0.05 vs. 3-day C. albicans/fluconazole
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Antenatal exposure to C. albicans did not result in
neuronal degeneration
In all experimental groups, no Fluoro-Jade C-positive
neurons were detected throughout the brain sections
(data not shown).
MPO and CD3
MPO- and CD3-positive cells were sporadically detected
in the cerebral vasculature of the choroid plexus and men-
inges. No MPO- and CD3-positive cells were found in the
cerebral white matter. No differences were seen between
all experimental groups (Additional file 1: Figure S1).
Ki67 and caspase-3
An increase in Ki67- and caspase-3-positive cells was
found in the white matter and hippocampus of the 5-day
C. albicans/fluconazole group compared to controls
(Fig. 7a–h, Table 2). Moreover, in the periventricular
white matter, an increase in caspase-3-positive cells was
observed.
Discussion
The main finding of this study is that 3 days of intra-
amniotic exposure to C. albicans resulted in increased
microglial and astrocyte activation with subsequent focal
white matter disturbances in the preterm ovine brain. At
this stage, C. albicans-positive CSF cultures were
detected without C. albicans-positive immunostainings
of the brain. This may indicate that cerebral inflamma-
tion and injury in the acute phase after intra-amniotic C.
albicans delivery is not caused by invasion of C. albicans
in the brain parenchyma [25, 26]. This concept is
supported by the absence of neutrophils in the brain
parenchyma since neutrophils are known to aggravate
disruption of the blood-brain barrier promoting further
invasion of C. albicans in the brain [25]. However, we
cannot rule out the possibility that low titers invaded the
brain, since the initial phase of C. albicans invasion does
not require a disruption of the blood-brain barrier and
such low fungal burden of the brain cannot be detected
by histology or immunofluorescence [15, 25].
Since C. albicans was not detected in the fetal brain,
we considered that severe systemic immune activation,
as shown in the present and previous studies [16, 17],
was (primarily) responsible for the acute changes ob-
served in the fetal brain 3 day post-C. albicans infection
of the amniotic cavity for the following reasons: Pro-
inflammatory cytokines, such as IL-6, contribute to acti-
vation of the endothelium of the blood-brain barrier,
which in turn activate adjacent microglia and astrocytes,
ultimately resulting in a cerebral inflammatory response
[27–31]. In line with this, systemic inflammation is
known to be causally involved in the induction of white
matter injury—as seen in our model [32, 33]. In
Fig. 3 H&E-stained brain sections of control animals and 5-day C. albicans-/fluconazole-treated animals. Control animals (a, b) showed no to mild
gliosis, and the 5-day C. albicans-/fluconazole-treated animals (c, d) showed severe gliotic foci in white matter of the gyral crest. a and c at ×25
magnification (scale bar = 500 μm) and b and d at ×200 magnification, scale bar = 100 μm
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Fig. 4 Antenatal exposure to C. albicans caused microglia activation and subsequent myelin disturbances in the white matter. Significant increase
(*p < 0.05) of the area fraction of IBA-1 (a–d) immunoreactivity (IR) was observed in all C. albicans-exposed animals compared to controls irrespective
of fluconazole (F) treatment. Significant increase (*p < 0.05) of the area fraction of CD68 IR (e–h) was observed in animals of the 5-day C. albicans/
fluconazole group. A decrease of MBP IR (i–l) was observed which did not reach significance (#p < 0.1) in the 3-day C. albicans-exposed group
compared to the controls irrespective of fluconazole treatment. Representative figures show that the area fraction of the IBA-1 IR is higher in
the 3-day C. albicans group (c) and 5-day C. albicans-/fluconazole-treated group (d) compared to the control group (b). Morphological analysis
showed a higher density of amoeboid microglia present in the white matter after C. albicans exposure (inserts). In these regions with microglia
activation, myelin disturbances, and loss of myelin fibers were found in the 3-day C. albicans-exposed (g) and the 5-day C. albicans-/fluconazole-treated
(h) group. Figures of the 3-day C. albicans-/fluconazole-treated group are not depicted here. Images taken at ×100 magnification (insert at
×400 magnification), scale bar = 500 μm
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addition, IL-6 was shown to be involved in the inhibition
of neurogenesis [28] and the development of hyper-
excitable neurological conditions including epilepsy,
psychoses, anxiety, and autism spectrum disorders in ex-
perimental models [34].
Notably, increased circulatory IL-6 concentrations were
not always paralleled by positive blood cultures in our
study. This finding can be explained by earlier studies
[35, 36] in which the presence of a pro-inflammatory trig-
ger in the amniotic fluid caused systemic inflammation
without migration of micro-organisms or their compo-
nents into the fetal circulation.
Intra-amniotic C. albicans caused a heterogeneous pat-
tern of cerebral immune activation as illustrated by in-
creased IBA-1 immunoreactivity in all C. albicans-exposed
animals. These regions of overt microgliosis were strongly
Fig. 5 Antenatal exposure to Candida albicans caused microglial (IBA-1) and astrocyte (GFAP) activation in the hippocampus. A significant
increase (*p < 0.05) of the area fraction of IBA-1 (a–d) and GFAP (e–h) immunoreactivity (IR) was observed in all C. albicans-exposed animals
compared to controls irrespective of fluconazole (F) treatment (a, e). No significant changes were found in the fluconazole-treated animals
compared to controls. Representative figures show that the area fraction of the IBA-1 IR and GFAP IR was higher in the 3-day C. albicans group
(c, g) and 5-day C. albicans-/fluconazole-treated group (d, h) compared to the control group (b, f). Images at ×20 magnification (inserts at
×200 magnification), scale bar = 100 μm
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associated with white matter injury within these specific
regions. Moreover, expression of CD68, which is import-
ant for the phagocytic activity of macrophages/microglia,
was increased at 5 days post exposure and might play a
prominent role in the clearance of debris including injured
mature oligodendrocytes and myelin [37].
White matter injury in this study was illustrated by re-
duction of MBP IR at 3 days post C. albicans exposure,
disrupted myelin texture in all C. albicans-exposed
animals and a deficit of mature oligodendrocytes which
was most prominent in the 5-day C. albicans/fluconazole
group. This white matter injury is considered to be the
result of activated microglia as seen in our study, which
produce cytokines, free radicals, nitric oxide, and exci-
totoxic amino acids, all detrimental for oligodendrocytes
and myelin [7, 38]. In addition, the most prominent loss
of mature oligodendrocytes in the 5-day C. albicans/fluz-
onazole group is most likely the result of clearance of
Fig. 6 Myelin disturbances are accompanied by a loss of mature oligodendrocytes. A significant decrease (*p < 0.05) of the ratio between
CNPase-positive mature oligodendrocytes and total number of cells of oligodendroglial lineage (Olig2-positive) was observed following 3-day
C. albicans and fluconazole (F) treatment and 5-day C. albicans-exposed groups and fluconazole treatment compared to controls. a, b graphical
representation of the CNPase (a) and Olig2 (b) data; (c) graphical representation of the CNPase/Olig2 ratio; d–e representative figures of CNPase/
Olig2 double stain in (d) controls and (e) 5-day C. albicans-exposed animals indicating an apparent loss of CNPase-positive cells. Images taken at
×200 magnification (insert at ×400 magnification), scale bar = 100 μm
Fig. 7 Antenatal exposure to C. albicans resulted in increased proliferation and apoptosis in the subcortical white matter and hippocampus. A
significant increase (*p < 0.05) of Ki67- and caspase-3-positive cells were observed following 5-day C. albicans with fluconazole treatment in the
white matter (e, g) and hippocampus (f, h) compared to controls (a–d). Images taken at ×200 magnification, scale bar = 100 μm
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these cells by phagocytizing microglia as previously stated.
This deficit was paralleled by replenishment of the oligo-
dendrocyte pool via two mechanisms. First, oligodendro-
cyte progenitors could migrate to the site of injury [39,
40]. Second, increased oligodendrocyte numbers could be
the consequence of increased proliferation [39, 41], which
would be consistent with our Ki67 data. However, in-
creased Ki67-positive cells do not exclusively identify
oligodendrocyte proliferation but could also comprise
other cell types. In particular, the increase of Ki67-positive
cells could also, in part, account for microglial prolifera-
tion, since we observed an increase of microglia within
these regions.
Nonetheless, the observed replenishment of oligoden-
drocytes is considered to be initiated as compensation
for the observed reduction of mature oligodendrocytes
[39, 41]. It is tempting to speculate that these progenitors
might fail to mature into a functional myelin-producing
oligodendrocyte since this phenotype has previously been
reported in experimental models of perinatal stress [42–44]
and in human neonates with periventricular leukomalacia
[39]. Finally, such oligodendrocyte maturation arrest corre-
lates with motor deficit characteristic for cerebral palsy [38,
44, 45]. In conjunction with white matter injury, grey mat-
ter injury is increasingly recognized as a contributor to ad-
verse neurodevelopmental outcome [35]. However, in our
study, no degenerating neurons were observed [22, 23]. Al-
though it is not likely that neurodegeneration is already per-
tinent in the 5-day C. albicans/fluconazole group, we
cannot exclude the possibility that the absence of Fluoro-
Jade staining at 5 days post exposure is the result of already
degenerated and dead neurons. In addition, cerebral palsy
also comprises cognitive impairments [7, 8] for which
we analyzed the hippocampus in which a similar in-
flammatory response was observed which is consistent
with our previous results [21, 46].
We previously reported that intra-amniotic C. albicans
rapidly colonizes the amniotic fluid, causing inflammation
of the fetal skin and lungs, and progresses into a fetal
systemic inflammatory response causing fetal death within
5 days after exposure [16, 17]. In the present study, we
show that fluconazole administration eradicated C.
albicans from the CSF and reduced systemic inflamma-
tion. Importantly, reduction of the fungal burden and in-
hibition of systemic immune activation following
fluconazole treatment was not accompanied by attenu-
ation of cerebral inflammation and injury. Multiple studies
have demonstrated that cerebral inflammation acquired
during early fetal development continues postnatally and
might even persist into adulthood [47, 48]. Therefore, we
consider that the observed cerebral inflammatory re-
sponse following intra-amniotic C. albicans exposure is a
persistent reaction that is initiated by peripheral immune
activation. Although fluconazole treatment did not protect
against structural cerebral injury in this acute phase, the
observed inhibition of systemic immune activation might
be clinically relevant, since prolonged and aberrant
systemic immune activations are known to induce blood-
brain barrier disruption, thereby facilitating cerebral inva-
sion of C. albicans and substantially aggravating cerebral
injury resulting in increased morbidity and mortality [26].
Collectively, previous and current findings suggest that
timing of infection and the start of antifungal treatment
regimen are important in the initiation, maintenance, and
possible resolution of neuroinflammation and structural
injury in the fetal brain. The current study provides im-
portant insight in the sequelae of events that contribute to
induction of adverse outcomes of the premature brain fol-
lowing intra-amniotic C. albicans infection. In addition,
this study points out that fluconazole treatment should be
started immediately after intra-amniotic exposure to C.
albicans considering the narrow therapeutic time window
to reduce morbidity and mortality. Therefore, further re-
search should focus on timing, frequency, and dosing of
antifungals in the presence or absence of immunomodula-
tory treatment [49].
Fluconazole treatment was not associated with adverse
effects in our study, which is in line with the findings of
Table 2 Ki67- and caspase-3-positive cells
Control 1-day fluconazole 3-day C. albicans 3-day C. albicans
and fluconazole
5-day C. albicans
and fluconazole
Ki67 + cells/mm2
White matter 11.2 (7.2) 41.6 (38.7) 21.9 (16.4) 54.7 (71.0) 56.0 (31.1)*
Periventricular white matter 7.6 (9.1) 14.4 (11.2) 17.6 (14.2) 8.6 (10.7) 20.9 (18.9)
Hippocampus 5.6 (4.2) 16.8 (13.6) 22.2 (27.5) 13.1 (13.0) 33.4 (27.0)*
Caspase-3 + cells/mm2
White matter 12.8 (13.6) 14.1 (11.1) 23.7 (33.2) 16.9 (6.8) 40.2 (22.6)*
Periventricular white matter 26.1 (11.4) 35.4 (24.4) 93.4 (110.2) 46.4 (29.1) 155.1 (22.4)*
Hippocampus 364.3 (175.3) 264.4 (19.6) 443.2 (198.8) 313.4 (117.0) 726.3 (317.9)*
Ki67- and caspase-3-positive cells expressed as mean (±SD)
*p < 0.05 vs. control
Ophelders et al. Journal of Neuroinflammation  (2016) 13:29 Page 10 of 12
Maneenil and colleagues in the same model [16] and
studies demonstrating that teratogenic effects of flucona-
zole are exclusively seen when used in the first trimester
at higher doses and after multiple gifts [50]. The admin-
istered fluconazole dose in this study mimics the amount
used in systemic neonatal candidiasis in which no ad-
verse long-term brain pathology and behavioral deficits
are currently described [50]. In addition, clinical in utero
administration of fluconazole prolonged pregnancy in
two cases of intra-amniotic C. albicans infection without
adverse treatment effects on the fetus [13].
We note that our study has several limitations. We only
tested one dose and frequency of fluconazole administra-
tion. In addition, we were not able to correlate histological
changes to functional neurological outcomes. However,
several studies previously established an association be-
tween endotoxin-induced chorioamnionitis and functional
electro-encephalogram (EEG) changes [43, 51, 52].
Conclusions
We have shown that intra-amniotic exposure to C. albicans
results in an acute systemic and neuroinflammatory
response with concomitant white matter injury. Although
systemic immune activation was significantly inhibited fol-
lowing fluconazole treatment, modulation of the cerebral
inflammatory response and prevention of concomitant
white matter injury was not found.
This study forms the essential basis for follow-up studies
in which the timing, frequency, and dosing of antifungal
treatment must be explored, and alternative/additional
neuroprotective treatment options including immuno-
modulatory interventions can be tested.
Additional file
Additional file 1: Figure S1. Antenatal exposure to C. albicans does not
result in infiltration of peripheral immune cells. (A–B) representative pictures
of CD3-positive T lymphocytes in the meninges of (A) controls and (B) 5-day
C. albicans/fluconazole animals. (C–D) representative pictures of MPO-
positive neutrophils in the choroid plexus of (C) controls and (D) 5-day C.
albicans/fluconazole animals. (TIF 20.7 mb)
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